Skip to main content

Gilead Sciences Archives

COVID treatment studied by VUMC gains FDA approval

Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Read more


New study supports remdesivir as COVID-19 treatment

Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

Read more


Blueprint for rebuilding the heart

May. 9, 2019—Young-Jae Nam and colleagues are discovering how to express specific factors in connective tissue cells to turn them into heart muscle cells.

Read more


Block estrogen to treat lung disease

Aug. 17, 2017—Based on findings from Vanderbilt investigators and others, clinical trials of estrogen inhibition for pulmonary arterial hypertension have recently been approved and funded by the National Institutes of Health.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more